en · de · es · fr · pt
ipamorelin-notes.peptides1004.com › News › �ƒŒ景与分子特征 — Complete Guide

�ƒŒ景与分子特征 — Complete Guide

By Editorial Desk · published 2025-12-02 · last reviewed 2025-12-22 · News

If you have been reading about certificate of analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2025-12-22. Numbers and descriptions here follow the published literature rather than marketing material.

背景与分子特征

Ipamorelin 是一种合成五肽,序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2,分子式 C38H49N9O5,游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素(GHS)家族,作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道,设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。

在 GHS 家族中,早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放,并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性,对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同,而完整的分子解释仍有待补充。需要区分的是,选择性是研究观察中的相对程度,并非绝对界限。

Background and Receptor Selectivity

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.

The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.

Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.

Ipamorelin at a glance

PropertyValueNotes
分子式C38H49N9O5五肽,C 端酰胺化
分子量约 711.85 g/mol游离碱形式
外观白色至类白色冻干粉研究用材料的常见形态
溶解性溶于水及 DMSO 等极性溶剂建议现配现用
储存温度-20 °C 或更低干燥、避光、限制冻融次数

Ipamorelin Background and Receptor Selectivity

Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.

Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.

Related pages on this site

Handling Storage And Analytical Control

Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.

In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.

Background And Receptor Mechanism

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.

Storage Stability and Analytical Verification

Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.

Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.

Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.

Further detail

Motif discovery happens in three major phases. A pre-processing stage where sequences are meticulously prepared in assembly and cleaning steps. Assembly involves selecting sequences that contain the desired motif in large quantities, and extraction of unwanted sequences using clustering. Cleaning then ensures the removal of any confounding elements. Next there is the discovery stage. In this phase sequences are represented using consensus strings or Position-specific Weight Matrices (PWM). After motif representation, an objective function is chosen and a suitable search algorithm is applied to uncover the motifs. Finally the post-processing stage involves evaluating the discovered motifs.

Psilocybin oral: 5–6 hours LSD oral: 7–11 hours (dose-dependent) Mescaline oral: 10–11 hours (range 6–14 hours) (dose-dependent) Dimethyltryptamine (DMT) inhaled: 5–20 minutes Ayahuasca (oral DMT with an MAOITooltip monoamine oxidase inhibitor): 4–6 hours 5-MeO-DMT inhaled: 5–20 minutes 2C-B oral: 3–5 hours (range 2–8 hours) The shortest-acting oral psychedelics are the less-well-known ASR-3001 (5-MeO-iPALT) (1.5–2.5 hours) and 4-HO-DiPT (2–3 hours), while the longest-acting known psychedelic is 2C-G-5 (32–48 hours). However, DOx psychedelics like DOM and the FLY psychedelic Bromo-DragonFLY (DOB-DFLY) reportedly may produce effects lasting for up to a few days at high doses.

=== United Kingdom === Lycium barbarum had been introduced in the United Kingdom in the 1730s by The Duke of Argyll, but the plant was mostly used for hedges and decorative gardening. The UK Food Standards Agency (FSA) had initially placed goji berry in the Novel Foods list. That classification would have required authorisation from the European Council and Parliament for marketing. However, on 18 June 2007, the FSA concluded that there was a significant history of consumption of the fruit before 1997, indicating its safety, and thus removed it from the list.

Type 1 diabetes, in which the immune system attacks the pancreas, is "extremely rare" in cats, unlike in dogs and humans. Type 2 diabetes is responsible for 80–95% of diabetic cases. They are generally severely insulin dependent by the time symptoms are diagnosed. Glipizide for T2DM are not known to be effective in cats, unlike in humans. Gestational diabetes, which occurs in humans and dogs, has never been found in cats. Insulin resistance and diabetes in cats can also have a component of hypersomatotropism (an excess of growth hormone, also leading to acromegaly) and hyperadrenocorticism. In some cats, cancer causes the loss of pancreatic islets.

Sources: en.wikipedia.org

Supporting material

=== Gray baby syndrome === Intravenous chloramphenicol use has been associated with the so-called gray baby syndrome. This phenomenon occurs in newborn infants because they do not yet have fully functional liver enzymes (i.e. UDP-glucuronyl transferase), so chloramphenicol remains unmetabolized in the body. This causes several adverse effects, including hypotension and cyanosis. The condition can be prevented by using the drug at the recommended doses, and monitoring blood levels.

==== Sides are drawn ==== For the latter half of 2003; sides continued to be drawn in the feud as The Source magazine publicly showed support of Ja Rule's in the conflict. The magazine's co-owner at the time Raymond "Benzino" Scott took notice of the ongoing feud as he was involved in a separate public quarrel with Eminem, plausibly displaying his support for Ja Rule in a retaliatory act as Eminem had demonstrated full support for 50 Cent and G-Unit. The toll of the feud began to put itself on display for Ja Rule and Murder Inc by the latter half of 2003; the album Blood in My Eye was released on November 4, 2003 with a heavy emphasis on responding to the feud with both 50 Cent, G-Unit, and Eminem. Despite receiving mixed-to-positive reviews, Blood in My Eye failed to achieve a certification, selling a total of approximately 400,000 copies, indicative of the damage to Murder Inc's public image amidst the feud and their own legal issues with the federal government. Amidst the conflict, Ja Rule still had the support of various high-profile figures within the community, such as Fat Joe and Jadakiss who would go on to appear on Ja Rule's 2004 album R.U.L.E. in the form of the track New York. The album showed a slight return for Ja Rule commercially as it would outsell its predecessor and receive a gold certification, led by the success of New York as a single. The song continued to maintain tensions with 50 Cent and G-Unit as it was perceived to be a subliminal diss track against both 50 Cent and G-Unit member Lloyd Banks, mocking the latter's then-recent single "On Fire".

== Nutrient pollution and eutrophication == Excessive nutrient inputs, particularly nitrogen and phosphorus from agricultural runoff, sewage, and urban development, lead to eutrophication. This process results in algal blooms that reduce water clarity and oxygen levels, adversely affecting aquatic plants. In eutrophic conditions, submerged plant communities often decline, replaced by phytoplankton-dominated systems. This shift reduces habitat complexity and the availability of refuges for invertebrates and fish. Additionally, (micro)organisms decomposing algae consume oxygen, creating hypoxic "dead zones" where aquatic life cannot survive.

Mackay snakehandler Ram Chandra traveled around Queensland and northern NSW, in part funded by the sugar industry. Sugarcane growers began to have trouble finding workers due to fears around the taipan. To counteract fears, the Queensland Cane Growers' Council produced an article in 1956 to calm panic, and Eric Worrell and David Fleay pointed out the snake's inherent shyness. In 1949 and 1950, 19-year-old snake handler Kevin Budden visited north Queensland to catch a taipan in a quest to develop antivenom. On 27 July 1950, he caught a specimen sunning itself in a rubbish dump on the outskirts of Cairns by putting his foot on it, grasping it by the neck with his left hand and letting it coil around his arm. He then walked to a main road and hailed a passing truck to take him to the house of local naturalist S.E. Stephens. Once there, the taipan escaped his grasp as he attempted to adjust his hold and bit his hand. Despite this, he secured the snake before going to hospital. He became paralysed later that day and succumbed early the following afternoon despite ventilation and large doses of tiger snake antivenom. Before he died, Budden requested the snake be sent to the Commonwealth Serum Laboratories, which in turn forwarded it to Fleay for milking. Fleay did so successfully, but found wrestling with the surprisingly strong and muscular subject to be difficult. They procured 78 mg of whitish venom, which led to the development of taipan antivenom. The snake itself became a minor celebrity, discussed in many newspapers at the time.

Davidson, Alan (1979). North Atlantic Seafood. ISBN 0-670-51524-8. Kurlansky, Mark (1997). Cod: A Biography of the Fish That Changed the World. New York: Walker. ISBN 0-8027-1326-2. Sanjuán, Gloria (2009). La Cocina del Bacalao. Madrid: Libro Hobby. ISBN 978-84-9736-242-9.

Sources: en.wikipedia.org

Frequently asked questions

Ipamorelin 与 GHRP-6 有什么不同?

两者都是 GHS-R1a 激动剂,但 ipamorelin 在研究中显示出更高的生长激素释放选择性。早期资料显示它对皮质醇、催乳素与食欲的刺激弱于 GHRP-6。这些差异是相对程度,而非绝对区分。

Ipamorelin 是已批准药物吗?

公开资料中它主要以研究用肽的形式出现,未获主要监管机构批准用于治疗。可得材料通常标注仅供研究使用。任何临床用途的宣称都缺少监管依据。

为什么它的序列含有非天然氨基酸?

序列中的 Aib 与 D-2-Nal 等非天然残基可提高对肽酶的抵抗能力,并影响受体结合的构象。这类修饰在合成肽设计中较为常见。它们也使常规氨基酸分析需要额外步骤才能确认序列。

Aib 残基起什么作用?

Aib 即 α-氨基异丁酸,是一种非蛋白质源氨基酸,其侧链为两个甲基。它在肽链中倾向于诱导螺旋构象并限制骨架的柔性。这种刚性被认为有助于抵抗蛋白酶切割。

Network